Robert Kiyosaki, author of "Rich Dad Poor Dad," has long advocated Bitcoin, gold, and silver as financial assets. Despite his bold price predictions for these assets, none of his nine checked price targets met their deadlines, though five were reached later. He accurately predicted Bitcoin's 2022 crash below $20,000 and silver surpassing $100 in 2026. Kiyosaki's advice emphasizes buying assets over liabilities and accumulating during market downturns, but his timing and specific forecasts have been unreliable. Investors can learn from his focus on financial education but should be cautious about his price targets.
Robert Kiyosaki's views on Bitcoin and precious metals provide context for cryptocurrency trends. For readers following crypto, here is Pluang's market snapshot as of Nov 07, 2026 23:02 WIB: Of 50 major cryptocurrencies, 10 rose and 39 fell today. Notable movers include BAL at Rp16.297 (+11.14%), ZIL at Rp31 (-9.16%, with 29% sell and 71% buy order activity), and EOS at Rp12.649 (+8.13%).
LayerZero (ZRO) fell 12.77% in 24 hours, leading declines among major cryptocurrencies as 75 of the top 90 coins lost value. Other notable drops include Ethena (ENA) down 11.49%, Worldcoin (WLD) down 10.95%, and Uniswap (UNI) down 10.67%. Meanwhile, ...
Valour launched a new exchange-traded product (ETP) for the PUMP token on Sweden's Spotlight Stock Market, allowing investors to access PUMP through traditional brokerage accounts with a 1.9% management fee. Despite this institutional milestone, PUMP...
Ethereum is trying to stabilize near $2,245 after a sharp decline, but ongoing institutional selling has led to $365 million in ETF outflows over one week. The key support level at $2,200 is under threat, with potential further drops to $2,100 or eve...
Cathie Wood, founder of ARK Invest, forecasts Bitcoin could hit around $730,000 by 2030, with a bull case of $1.5 million. ARK Invest manages about $16 billion, focusing on disruptive tech and crypto stocks like Circle and Coinbase. While ARK's flags...
Clarivate PLC's shares surged 40% following a strong third-quarter performance and a $600 million divestment in life sciences, which helped reduce the company's leverage and sharpen its business focus. Despite modest organic growth and some leverage ...
